The aim of this study is to assess the efficacy and safety of minocycline in improving functional outcome among patients with acute ischaemic stroke receiving intravenous thrombolysis.
Age between 18 and 80 years;
Patients with acute ischaemic stroke confirmed by CT or MRI;
Having received or planning to receive intravenous thrombolysis within 4.5 hours of onset or within an extended window of 4.5-24 hours based on guideline recommendations (The intravenous thrombolytic drugs include: alteplase, tenecteplase, reteplase or recombinant human prourokinase);
The study drug can be applied before intravenous thrombolysis or within 2 hours after the initiation of intravenous thrombolysis;
mRS score ≥ 2 prior to onset of the current stroke;
History of pseudomembranous colitis or antibiotic-associated colitis;
Known allergy or intolerance to tetracycline antibiotics or any component of minocycline;
Known resistance to other tetracyclines;